Oruka Therapeutics Q2 2024 Earnings Report

Oruka Therapeutics EPS Results

• Actual EPS: -$25.92
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Oruka Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Oruka Therapeutics Announcement Details

• Quarter: Q2 2024
• Date: 8/1/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Oruka Therapeutics (NASDAQ:ORKA) is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy. In addition to ONCT-01, Oruka’s pipeline includes multiple preclinical programs directed at key targets such as MDM2-p53 and MYC, reflecting a broad strategy to address unmet needs across various tumor types. The company’s research efforts extend to both monotherapy and combination therapy approaches to enhance anti‐tumor activity.

Headquartered in the United States, Oruka Therapeutics became a publicly traded company in 2022 and is listed on the NASDAQ under the symbol ORKA. The organization is led by a management team with extensive experience in peptide chemistry, oncology drug development and clinical operations. Oruka continues to advance its technology platform and pipeline toward the goal of delivering innovative cancer treatments to patients worldwide.